AbCellera

11:45 AM - 12:00 PM (PDT), Tuesday, June 14, 2022

AbCellera's technology increases the speed and likelihood of finding best-in-class and first-in-class antibodies, drug developers of all sizes, from early-stage biotech to large biopharmaceutical companies partner with us for their drug programs. AbCellera has transformed the way antibody-based therapies are discovered by replacing fragmented, traditional workflows with vertically integrated technology stack that solves all steps in the antibody discovery process.


Large pharma partners come to us to unlock drug targets and modalities that have been intractable using traditional workflows, such as bispecific T cell engagers and G protein-coupled receptors. Early-stage companies work with AbCellera to advance their programs immediately by accessing our best-in-world technology without having to build it themselves.


We share in the success of the molecules we discover through deal structures that include research and milestone payments and royalties on net sales.

Ticker:
ABCL
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
British Columbia
Company HQ Country:
Canada
Year Founded:
2012
Main Therapeutic Focus:
Lead Product in Development:
Bebtelovimab
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
AbCellera Biologics